Jacobs Levy Equity Management’s Vir Biotechnology VIR Stock Holding History

Jacobs Levy Equity Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	136,335 -1,306,001	-91%	-$12.4M	0.01%	662
2026 Q1	$12.9M	Buy	+1,442,336	New	+$11.5M	0.05%	273
2025 Q4	–	Sell	-96,717	Closed	-$552K	–	1068
2025 Q3	$552K	Sell	96,717 -48,581	-33%	-$248K	﹤0.01%	805
2025 Q2	$732K	Buy	145,298 +89,846	+162%	+$482K	﹤0.01%	816
2025 Q1	$359K	Buy	+55,452	New	+$493K	﹤0.01%	959
2024 Q4	–	Sell	-350,265	Closed	-$2.62M	–	1050
2024 Q3	$2.62M	Buy	350,265 +33,473	+11%	+$291K	0.01%	551
2024 Q2	$2.82M	Buy	316,792 +6,701	+2%	+$64.3K	0.01%	545
2024 Q1	$3.14M	Buy	310,091 +16,615	+6%	+$169K	0.01%	516
2023 Q4	$2.95M	Buy	293,476 +12,876	+5%	+$118K	0.01%	536
2023 Q3	$2.63M	Buy	+280,600	New	+$4M	0.02%	518
2022 Q4	–	Sell	-19,169	Closed	-$370K	–	1045
2022 Q3	$370K	Buy	+19,169	New	+$487K	﹤0.01%	870

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Jacobs Levy Equity Management's VIR Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Vir Biotechnology (VIR) stake by 91% in Q2 2026, selling an estimated $12.4M and leaving 136,335 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #662.

Jacobs Levy Equity Management first reported a position in VIR in Q3 2022 and has held it in 11 quarters since. The position peaked at $12.9M in Q1 2026. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Jacobs Levy Equity Management held 136,335 shares of Vir Biotechnology worth $1.39M as of Q2 2026.
Jacobs Levy Equity Management sold 1,306,001 Vir Biotechnology shares in Q2 2026, an estimated $12.4M.
Vir Biotechnology made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #662 holding.
Jacobs Levy Equity Management first reported a position in Vir Biotechnology in Q3 2022 and has held it in 11 quarters since.
Jacobs Levy Equity Management's Vir Biotechnology position peaked at $12.9M in Q1 2026.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.